- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- amphetamine extended-release oral suspension, 2.5 mg/mL, Placebo extended-release oral suspension
- Drug
- Lead sponsor
- Tris Pharma, Inc.
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- TRI102, Placebo
- Drug · Other
- Lead sponsor
- Tris Pharma, Inc.
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 5
- States / cities
- Newport Beach, California • Las Vegas, Nevada • Durham, North Carolina + 2 more
- Conditions
- Excessive Daytime Sleepiness, Cataplexy, Narcolepsy
- Interventions
- FT218, Placebo
- Drug
- Lead sponsor
- Avadel
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 38
- States / cities
- Anniston, Alabama • Auburn, Alabama • Birmingham, Alabama + 32 more
- Conditions
- Advanced Parkinson's Disease
- Interventions
- Levodopa carbidopa intestinal gel (LCIG), Placebo gel, Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets, Placebo (PBO) oral capsules, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
- Drug · Device
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Englewood, Colorado • Washington D.C., District of Columbia + 5 more
- Conditions
- Advanced Parkinson's Disease
- Interventions
- Levodopa carbidopa intestinal gel (LCIG), Placebo Gel, Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets, Placebo (PBO) oral capsules, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
- Drug · Device
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Fountain Valley, California • Oceanside, California + 8 more
- Conditions
- Schizophrenia
- Interventions
- TV-46000, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 13 Years to 65 Years
- Enrollment
- 336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 67
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 57 more
- Conditions
- Idiopathic Hypersomnia
- Interventions
- FT218, Placebo
- Drug · Other
- Lead sponsor
- Avadel
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 7
- States / cities
- Boulder, Colorado • Winter Park, Florida • Stockbridge, Georgia + 4 more
- Conditions
- Schizophrenia
- Interventions
- TV-46000, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 13 Years to 65 Years
- Enrollment
- 544 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 73
- States / cities
- Little Rock, Arkansas • Rogers, Arkansas • Anaheim, California + 58 more
- Conditions
- Carpometacarpal (CMC) Osteoarthritis
- Interventions
- Triamcinolone Acetonide extended release suspension
- Drug
- Lead sponsor
- Marie Badalamente
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Stony Brook, New York
- Conditions
- Delayed Emergence From Anesthesia
- Interventions
- Methylphenidate HCl, Placebo
- Drug
- Lead sponsor
- Nicoleta Stoicea
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Opioid Use Disorder
- Interventions
- NTX/BUP, NTX/PBO-B, PBO-N/PBO-B
- Drug
- Lead sponsor
- Alkermes, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 20
- States / cities
- Oceanside, California • Orange, California • Lauderhill, Florida + 17 more